Printer Friendly

INAMED BRINGS PATENT INFRINGEMENT SUIT AGAINST BIOPLASTY

 INAMED BRINGS PATENT INFRINGEMENT SUIT AGAINST BIOPLASTY
 SANTA BARBARA, Calif., Nov. 27 /PRNewswire/ -- Inamed Corp. (NASDAQ: IMDC), headquartered here, today said that its McGhan Medical Corp. subsidiary had filed suit for patent infringement against Bioplasty Inc. and related parties.
 The complaint, which was filed in U.S. District Court in Minnesota, charges that Bioplasty, its supplier, Bio-Manufacturing Inc., and two individuals holding concurrent positions with these concerns, intentionally infringed upon patents for silicone gel- filled breast implant prostheses held by McGhan Medical by selling certain prostheses embodying these patents. The complaint further alleges that the infringement "has been willful and deliberate since defendants have had actual and constructive knowledge" of the existence of the said patents.
 According to Inamed Chairman Donald K. McGhan, the infringement against the company is covered under two separate patents acknowledged by the silicone medical device industry worldwide. The patents, U.S. 4,455,691 and U.S. 4,472,226, provide for a barrier against the potential transfer of silicone through the prosthesis shell. "These patents cover both process and product," he said.
 McGhan said he was "confident" that the court would find in favor of McGhan Medical and ultimately return "equitable damages and fees" in compensation for the infringement. "We regret having to take this action," said the chief executive officer, "but we believe it is now the only available means by which to adequately resolve this matter."
 Last week a U.S. Food and Drug Administration advisory panel recommended that breast implant products produced by McGhan Medical, Bioplasty and two other manufacturers remain on the market while additional safety data is gathered.
 Inamed Corp. is a medical device company with 13 operating subsidiaries in the United States and Europe. The company develops, manufactures and markets medical devices for the plastic and reconstructive, bariatric and general surgery markets. The company recently reported sales of over $31 million for the first nine months of 1991. Sales for 1990 were $35.7 million.
 -0- 11/27/91
 /CONTACT: Donald K. McGhan, chairman of Inamed, 805-684-6277; or Jimmy Caplan of Market Makers, 805-569-6919, or Rick Eisenberg of Eisenberg Communications, 212-496-6828, both for Inamed/
 (IMDC) CO: Inamed Corp. ST: California IN: MTC SU:


AL-SE -- LA003 -- 7633 11/27/91 09:02 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 27, 1991
Words:374
Previous Article:SANTA MONICA BANK'S BOARD OF DIRECTORS DECLARES 4TH QUARTER CASH DIVIDEND FOR 1991
Next Article:CARL'S JR. INTRODUCES NEW PRODUCT
Topics:


Related Articles
BIOPLASTY, INC., ANNOUNCES RECEIPT OF PATENT INFRINGEMENT COMPLAINT
BIOPLASTY RECEIVES BREAST IMPLANT PATENT
BIOPLASTY SUBMITS INVESTIGATIONAL DEVICE EXEMPTION (IDE) FOR ITS MISTI GOLD BREAST IMPLANTS
JURY INVALIDATES ORMCO PATENT FOR BIOMERICA SUBSIDIARY LANCER ORTHODONTICS
BIOPLASTY SETTLES PATENT INFRINGEMENT SUIT
BIO-VASCULAR REPORTS DISPUTE ON ROYALTIES
BIOPLASTY SETTLES PATENT INFRINGEMENT SUIT
BIOPLASTY, INC. FILES FOR PROTECTION UNDER CHAPTER 11 OF THE U.S. BANKRUPTCY CODE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters